Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of Formula (1):



(1)

wherein:

Cy is a group of Formula (2):



(2)

R_1, R_2, R_3, R_4 and R_5 are hydrogen, halogen, or hydroxy and at least one of R_1, R_2, R_3, R_4 and R_5 is halogen;

R_6 is hydrogen;

R_7 is straight-chained or branched C_{1-3}alkyl, substituted with one or more hydroxyl groups, or amino optionally substituted with one or more straight-chained or branched C_{1-3} alkyl groups which many be the same or different;

R_8 is hydrogen, methyl or ethyl;

R_9 is straight-chained or branched C_{1-6} alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of phenyl, para-hydroxyphenyl, para-fluorophenyl, para-chlorophenyl, C3-7 cycloalkyl, halogen and thienyl, C_{3-7}cycloalkyl; or phenyl;

R_{20} is hydrogen;

R_{10} is hydrogen or methyl or ethyl ;

R_{11} is straight-chained or branched C_{1-3} alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of amino; hydroxyl, carbamoyl, methanesulfonyl, ureide, guanidyl, N'-cyano-N"-methylguanidyl, sulfamoylamino, carbamoylmethylamino and methanesulfonylamino, and -CO-$N(R_{14})R_{15}$;

R_{12} is hydroxy;

R_{13} straight-chained or branched C_{1-6} alkyl[[,]];

R_{14} and R_{15}, which may be the same or different, are each hydrogen, straight-chained or branched ~~C_{1-3} alkyl~~ C_{1-4} alkyl optionally substituted with hydroxyl or methanesulfonyl;, C_{3-7}cycloalkyl, straight-chained or branched C_{1-4} alkoxy, straight-chained or branched C_{1-4} alkylsulfonyl, or pyridyl;

~~R_{18} and R_{19} together form cycloalkyl or C_{3-7} cycloalkenyl;~~

X is carbonyl or methylene;

Y is carbonyl;

or a pharmaceutically acceptable salt thereof.

2. (Previously presented) The compound according to claim 1,

wherein Cy in Formula (1) is a group of Formula (2);

or a pharmaceutically acceptable salt thereof.

3. (Previously presented) The compound according to claim 1,

wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R_1, R_2, R_3, R_4 and R_5 is halogen and the others are hydrogen or hydroxy;

or a pharmaceutically acceptable salt thereof.

4. (Previously presented) The compound according to claim 1,

wherein Cy in Formula (1) is a group of Formula (2) in which R_3 is halogen or R_2 and R_3 are the same kind of halogen;

or a pharmaceutically acceptable salt thereof.

5. (Previously presented) The compound according to claim 1,

wherein Cy in Formula (1) is a group of Formula (2) in which R_3 is halogen and R_1, R_2, R_4 and R_5 are hydrogen, or R_2 and R_3 are the same kind of halogen and R_1, R_4 and R_5 are hydrogen; or a pharmaceutically acceptable salt thereof.

Claims 6-13. (Canceled)

14. (Previously presented) The compound according to claim 1, wherein R_7 in Formula (1) is hydrogen or amino optionally substituted with one or more of the same of different kinds of straight-chained or branched C_{1-3} alkyl; or a pharmaceutically acceptable salt thereof.

15. (Previously presented) The compound according to claim 1, wherein R_8 in Formula (1) is hydrogen or methyl; or a pharmaceutically acceptable salt thereof.

16. (Previously presented) The compound according to claim 1, wherein R_9 in Formula (1) is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, cyclohexylmethyl or para-fluorobenzyl;
or a pharmaceutically acceptable salt thereof.

Claims 17-18. (Cancelled)

19. (Previously presented) The compound according to claim 1, wherein R_{11} in Formula (1) is methyl,

hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, tertbutylcarbamoyl, methoxycarbamoyl, methylcarbamoyl, methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl,;
or a pharmaceutically acceptable salt thereof.

Claim 20 Cancelled

21. (Previously presented) The compound according to claim 1, wherein R_{13} in Formula (1) is isopropyl, tert-butyl (tBu), or 1,1-dimethylpropyl;
or a pharmaceutically acceptable salt thereof.

22. (Previously presented) The compound according to claim 1, wherein in Formula (1) Cy is a group of Formula (2) in which at least one of R_1, R_2, R_3, R_4 and R_5 is halogen and the others are hydrogen or hydroxy;
R_8 is hydrogen or methyl;
R_9 is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl phenyl;
R_{11} is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl,

methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl, or methoxycarbamoyl;

R_{13} is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl—or 1,1-dimethyl-2-propenyl;

or a pharmaceutically acceptable salt thereof.

23. (Previously presented) The compound according to claim 1 which is selected from the group of compounds consisting of Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-Cl)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(3,4-F_2)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHOMe, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(2-pyridylcarbamoyl)ethylamide, N-(2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butyrylamino)-3-(3-tBu-4-hydroxyphenyl)propyl)urea, N-(2-(2-(2-amino-3-(4-fluorophenylpropanoyl-N-methylamino)-3-methyl)butyrylamino)-3-(3-tertbutyl-4-hydroxyphenyl)propyl)sulfamide, N-[2-(3-tertbutyl-4-hydroxyphenyl)-1-(methanesulfonylaminomethyl)ethyl]-2-[N-(4-fluorophenylalanyloyl)methylamino]-3-methylbutanamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-carbamidemethylethylamide, 2-((2-amino-3-(4-

fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-methanesulfonylmethylethylamide, 2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butyrylamino)-3-(3-tBu-4-hydroxyphenyl)propanol, 2-(1-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butyrylamino)-2-(3-tertbutyl-4-hydroxyphenyl)ethyl)-6-methyl-4-pyrimidinone, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-oxadiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,2,4-oxadiazol-5-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(thiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-triazol-2-yl)ethylamide, Tyr(2-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Tyr(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH_2, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH_2, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Me-

Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH_2, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH_2, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val- N-Et-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHtBu, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2SO_2CH_3$, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NHCH_2OH$, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NHCH_2OH$, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NHCH_2OH$, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)- NHEt, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2OH$, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2OH$, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2OH$, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NHCH_2OH$, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NHCH_2OH$, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NHCH_2OH$, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHcPr, and Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHnPr Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHiPr;

or a pharmaceutically acceptable salt thereof.

24. (Previously Presented) A pharmaceutical composition containing an effective amount of the compound according to claim 1 as an active ingredient and an inert pharmaceutically acceptable carrier.

25. (Previously Presented) A motilin receptor antagonist composition containing an effective amount of the compound according to claim 1 and an inert pharmaceutically acceptable carrier.

Claims 26-27. (Cancelled)

28. (Currently Amended) A compound of Formula (4):



(4)

wherein

Cy, R_6, R_8, R_9, R_{20}, R_{10}, R_{12}, R_{13}, X and Y are as defined in claim 1;

R_7' is straight-chained or branched C_{1-3}alkyl substituted with one or more protected hydroxyl groups , or protected amino optionally substituted with one or more straight-chained or branched C_{1-3} alkyl groups which may be the same or different; and

R_{11}" is straight-chained or branched C_{1-3} alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of amino, hydroxyl[[;]], carbamoyl, methanesulfonyl, ureide, guanidyl, N'-cyano-N"-methylguanidyl, sulfamoylamino, carbamoylmethylamino, and methanesulfonylamino, and -CO-N(R_{14})R_{15}, wherein R_{14} and R_{15} are as defined in claim 1,[[;]]
or a pharmaceutically acceptable salt thereof.

29. (Previously presented) A compound of Formula (5):



(5)

wherein:

Cy, R_6, R_8, R_9, R_{20}, R_{10}, R_{12}, R_{13}, X and Y are as defined in claim 1;

R_7" is straight-chained or branched C_{1-3}alkyl substituted with one or more optionally protected hydroxyl groups or amino optionally substituted with one or more different straight-chained or branched C_{1-3} alkyl groups which may be the same or different; and

R_{11}' is straight-chained or branched C_{1-3}alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of protected amino; protected hydroxyl, protected carbamoyl, protected ureide, protected guanidyl, protected N'-cyano-N"-methylguanidyl, protected sulfamoylamino, protected carbamoylmethylamino and protected methanesulfonylamino; $-CO-N(R_{14})R_{15}$ wherein R_{14} and R_{15} are those defined in claim 1 which are appropriately protected or a pharmaceutically acceptable salt thereof.

30. (Currently Amended) A compound of Formula (6):



(6)

wherein:

R_8 is hydrogen, methyl or ethyl;

R_9, is straight-chained or branched C_{1-6} alkyl optionally substituted with one or more groups which may be the same or different ant are selected from the group consisting of phenyl, para-hydroxyphenyl, para-fluorophenyl, para-chlorophenyl, C_{3-7} cycloalkyl, halogen and thienyl;

R_{20} is hydrogen or methyl or;

R_{10} is hydrogen or methyl or ethyl;

R_{12} is hydroxy;

R_{13} is straight-chained or branched C_{1-6} alkyl; and

Y is carbonyl;

P_1 is hydrogen or a protecting group of amine; and

R_{11}''' is straight-chained or branched C_{1-3}alkyl, carboxyl, straight-chained or branched C_{1-3}alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of amino hydroxyl, ~~methoxy, halogen,~~ carbamoyl, methanesulfonyl, ureide, guanidyl, N'-cyano-N"-methylguanidyl, sulfamoylamino, carbamoylmethylamino and methanesulfonylamino; straight-chained or branched C_{1-3} alkyl having protected amino or and -CO-N(R_{14})R_{15} wherein R_{14} and R_{15}, which may be the same or different, are hydrogen, straight-chained or branched C_{1-4} alkyl optionally substituted with hydroxy, C_{3-7} cycloalkyl, straight-chained or branched C_{1-4} alkoxy, straight-chained or branched C_{1-4}alkylsulfonyl, or pyridyl; or

a pharmaceutically acceptable salt thereof.

Claims 31-34. (Canceled)

35. (Previously Presented) The compound according to claim 1, wherein the substitution of the optionally substituted straight-chained or branched C_{1-3} alkyl as R_7 in formula (1) is halogen, hydroxyl or amino.